Pediatric gliomas, particularly those with V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations, present significant challenges in neuro-oncology with an incidence rate of 3 to 4 cases per 100,000 children.[1] Historically, children with BRAF V600E-mutated gliomas have had poor outcomes with conventional chemoradiotherapy strategies. This evidence concerns the gene BRAF and central nervous system cancer.